Chenodeoxycholic acid Leadiant (previously known as Chenodeoxycholic acid sigma-tau)

chenodeoxycholic acid

  • Email
  • Help

About

This is a summary of the European public assessment report (EPAR) for Chenodeoxycholic acid Leadiant. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Chenodeoxycholic acid Leadiant.

For practical information about using Chenodeoxycholic acid Leadiant, patients should read the package leaflet or contact their doctor or pharmacist.

What is Chenodeoxycholic acid Leadiant and what is it used for?

Chenodeoxycholic acid Leadiant is a medicine that contains the active substance chenodeoxycholic acid. This is a ‘primary bile acid’, which is a main component of bile (a fluid produced by the liver that helps to digest fats).

Chenodeoxycholic acid Leadiant is used to treat adults and children from one month of age with cerebrotendinous xanthomatosis. These patients cannot produce enough of the primary bile acid chenodeoxycholic acid due to genetic abnormalities that result in a lack of the liver enzyme sterol 27 hydroxylase. When primary bile acids are lacking, the body produces abnormal bile acids and other substances instead which accumulate throughout the body, causing damage.

Because the number of patients with this condition is low, the disease is considered ‘rare’, and Chenodeoxycholic acid Leadiant was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 16 December 2014.

Chenodeoxycholic acid Leadiant is a ‘hybrid medicine’. This means that it is similar to a ‘reference medicine’ containing the same active substance. The reference medicine for Chenodeoxycholic acid Leadiant is Xenbilox. However, Xenbilox differs from Chenodeoxycholic acid Leadiant in that it is authorised for a different use (to dissolve cholesterol gallstones).

How is Chenodeoxycholic acid Leadiant used?

Chenodeoxycholic acid Leadiant can only be obtained with a prescription and treatment should be started and supervised by a doctor experienced in treating cerebrotendinous xanthomatosis or other diseases of primary bile acid production.

Chenodeoxycholic acid Leadiant is available as capsules (250 mg) which are taken 3 times a day at approximately the same time every day. The daily dose is chosen and adjusted during treatment for each patient depending on the patient’s age, liver function and levels of bile acids in their blood and urine. For small children and children who cannot swallow capsules, the contents of the capsules can be mixed with sodium bicarbonate solution 8.4% to make a liquid.

For further information, see the package leaflet.

How does Chenodeoxycholic acid Leadiant work?

Chenodeoxycholic acid is one of the main primary bile acids produced by the liver. The chenodeoxycholic acid contained in this medicine replaces the patient’s missing chenodeoxycholic acid. This helps to reduce the production of abnormal substances and contributes to the normal activity of bile in the digestive system, thereby relieving the symptoms of the disease.

What benefits of Chenodeoxycholic acid Leadiant have been shown in studies?

Chenodeoxycholic acid Leadiant has been investigated in a study which looked at the records of 35 patients with cerebrotendinous xanthomatosis who received chenodeoxycholic acid for around 9 years. Among 23 patients for whom data on blood levels of bile acids were available, all had reductions in their levels (average reduction of 56–69 µmol/l). Among 14 patients for whom data on urine levels of bile acids were available, 79% (11 out of 14) had reduced levels at their most recent test. Most patients also had improvements in symptoms of the disease: all reported an improvement in diarrhoea, 89% of patients showed an improvement in their mental ability, 60% of patients showed improvement in mobility, and 85% and 77% of patients showed psychiatric improvement based on two different scores.

What are the risks associated with Chenodeoxycholic acid Leadiant?

The side effects seen with Chenodeoxycholic acid Leadiant are constipation and abnormal liver test values; however their frequency could not be reliably estimated from the available limited data. They were mild or moderate in severity and did not last.

For the list of restrictions, see the package leaflet.

Why is Chenodeoxycholic acid Leadiant approved?

Chenodeoxycholic acid has been used to treat cerebrotendinous xanthomatosis for about 40 years, although it was not licensed for this use. However, due to the rarity of the disease, there are still limited data available on the use of the medicine. Nevertheless, studies have shown that the medicine benefits patients and has no significant side effects. The Agency’s Committee for Medicinal Products for Human Use (CHMP) therefore decided that Chenodeoxycholic acid Leadiant’s benefits are greater than its risks and recommended that it be approved for use in the EU.

Chenodeoxycholic acid Leadiant has been authorised under ‘exceptional circumstances’. This is because it has not been possible to obtain complete information about Chenodeoxycholic acid Leadiant due to the rarity of the disease. Every year, the European Medicines Agency will review any new information that becomes available and this summary will be updated as necessary.

What information is still awaited for Chenodeoxycholic acid Leadiant?

Since Chenodeoxycholic acid Leadiant has been approved under exceptional circumstances, the company that markets this medicine will set up a registry to monitor the benefits and safety of the medicine.

What measures are being taken to ensure the safe and effective use of Chenodeoxycholic acid Leadiant?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Chenodeoxycholic acid Leadiant have been included in the summary of product characteristics and the package leaflet.

Other information about Chenodeoxycholic acid Leadiant

The European Commission granted a marketing authorisation valid throughout the European Union for Chenodeoxycholic acid sigma-tau on 10 April 2017. The name of the product was changed to Chenodeoxycholic acid Leadiant on 12 May 2017.

For more information about treatment with Chenodeoxycholic acid Leadiant, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Name Language First published Last updated
Chenodeoxycholic acid Leadiant : EPAR - Summary for the public BG = bălgarski 2017-05-05 2017-06-29
Chenodeoxycholic acid Leadiant : EPAR - Summary for the public ES = español 2017-05-05 2017-06-29
Chenodeoxycholic acid Leadiant : EPAR - Summary for the public CS = čeština 2017-05-05 2017-06-29
Chenodeoxycholic acid Leadiant : EPAR - Summary for the public DA = dansk 2017-05-05 2017-06-29
Chenodeoxycholic acid Leadiant : EPAR - Summary for the public DE = Deutsch 2017-05-05 2017-06-29
Chenodeoxycholic acid Leadiant : EPAR - Summary for the public ET = eesti keel 2017-05-05 2017-06-29
Chenodeoxycholic acid Leadiant : EPAR - Summary for the public EL = elliniká 2017-05-05 2017-06-29
Chenodeoxycholic acid Leadiant : EPAR - Summary for the public EN = English 2017-05-05 2017-06-29
Chenodeoxycholic acid Leadiant : EPAR - Summary for the public FR = français 2017-05-05 2017-06-29
Chenodeoxycholic acid Leadiant : EPAR - Summary for the public IT = italiano 2017-05-05 2017-06-29
Chenodeoxycholic acid Leadiant : EPAR - Summary for the public LV = latviešu valoda 2017-05-05 2017-06-29
Chenodeoxycholic acid Leadiant : EPAR - Summary for the public LT = lietuvių kalba 2017-05-05 2017-06-29
Chenodeoxycholic acid Leadiant : EPAR - Summary for the public HU = magyar 2017-05-05 2017-06-29
Chenodeoxycholic acid Leadiant : EPAR - Summary for the public MT = Malti 2017-05-05 2017-06-29
Chenodeoxycholic acid Leadiant : EPAR - Summary for the public NL = Nederlands 2017-05-05 2017-06-29
Chenodeoxycholic acid Leadiant : EPAR - Summary for the public PL = polski 2017-05-05 2017-06-29
Chenodeoxycholic acid Leadiant : EPAR - Summary for the public PT = português 2017-05-05 2017-06-29
Chenodeoxycholic acid Leadiant : EPAR - Summary for the public RO = română 2017-05-05 2017-06-29
Chenodeoxycholic acid Leadiant : EPAR - Summary for the public SK = slovenčina 2017-05-05 2017-06-29
Chenodeoxycholic acid Leadiant : EPAR - Summary for the public SL = slovenščina 2017-05-05 2017-06-29
Chenodeoxycholic acid Leadiant : EPAR - Summary for the public FI = suomi 2017-05-05 2017-06-29
Chenodeoxycholic acid Leadiant : EPAR - Summary for the public SV = svenska 2017-05-05 2017-06-29
Chenodeoxycholic acid Leadiant : EPAR - Summary for the public HR = Hrvatski 2017-05-05 2017-06-29

This EPAR was last updated on 22/08/2017 .

Authorisation details

Product details

Product details for Chenodeoxycholic acid Leadiant (previously known as Chenodeoxycholic acid sigma-tau)
NameChenodeoxycholic acid Leadiant (previously known as Chenodeoxycholic acid sigma-tau)
Agency product numberEMEA/H/C/004061
Active substance

chenodeoxycholic acid

International non-proprietary name (INN) or common name

chenodeoxycholic acid

Therapeutic area Metabolism, Inborn ErrorsXanthomatosis, Cerebrotendinous
Anatomical therapeutic chemical (ATC) code A05AA01
Additional monitoring

This medicine is under additional monitoring. This means that it is being monitored even more intensively than other medicines. For more information, see medicines under additional monitoring.

Treatment of rare diseases

This medicine has an "orphan designation" which means that it is used to treat life-threatening or chronically debilitating conditions that affect no more than five in 10,000 people in the European Union, or are medicines which, for economic reasons, would be unlikely to be developed without incentives.

Exceptional Circumstances

There were "exceptional circumstances" concerning the approval of this medicine. This happens when the applicant can show that they are unable to provide comprehensive data on the efficacy and safety of the medicine for which authorisation is being sought, due to the rarity of the condition it is intended for, limited scientific knowledge in the area concerned, or ethical considerations involved in the collection of such data.

Publication details

Publication details for Chenodeoxycholic acid Leadiant (previously known as Chenodeoxycholic acid sigma-tau)
Marketing-authorisation holder

Leadiant GmbH

Revision2
Date of issue of marketing authorisation valid throughout the European Union10/04/2017

Contact address:

Leadiant GmbH
Liebherrstrasse 22
80538 München
Germany


 

Product information

Product information

04/07/2017  Chenodeoxycholic acid Leadiant (previously known as Chenodeoxycholic acid sigma-tau) -EMEA/H/C/004061 -IB/0003/G

Name Language First published Last updated
Chenodeoxycholic acid Leadiant : EPAR - Product Information HR = Hrvatski 2017-05-05 2017-08-22
Chenodeoxycholic acid Leadiant : EPAR - Product Information HR = Hrvatski 2017-05-05 2017-08-22
Chenodeoxycholic acid Leadiant : EPAR - Product Information HR = Hrvatski 2017-05-05 2017-08-22
Chenodeoxycholic acid Leadiant : EPAR - Product Information HR = Hrvatski 2017-05-05 2017-08-22
Chenodeoxycholic acid Leadiant : EPAR - Product Information HR = Hrvatski 2017-05-05 2017-08-22
Chenodeoxycholic acid Leadiant : EPAR - Product Information HR = Hrvatski 2017-05-05 2017-08-22
Chenodeoxycholic acid Leadiant : EPAR - Product Information HR = Hrvatski 2017-05-05 2017-08-22
Chenodeoxycholic acid Leadiant : EPAR - Product Information HR = Hrvatski 2017-05-05 2017-08-22
Chenodeoxycholic acid Leadiant : EPAR - Product Information HR = Hrvatski 2017-05-05 2017-08-22
Chenodeoxycholic acid Leadiant : EPAR - Product Information HR = Hrvatski 2017-05-05 2017-08-22
Chenodeoxycholic acid Leadiant : EPAR - Product Information HR = Hrvatski 2017-05-05 2017-08-22
Chenodeoxycholic acid Leadiant : EPAR - Product Information HR = Hrvatski 2017-05-05 2017-08-22
Chenodeoxycholic acid Leadiant : EPAR - Product Information HR = Hrvatski 2017-05-05 2017-08-22
Chenodeoxycholic acid Leadiant : EPAR - Product Information HR = Hrvatski 2017-05-05 2017-08-22
Chenodeoxycholic acid Leadiant : EPAR - Product Information HR = Hrvatski 2017-05-05 2017-08-22
Chenodeoxycholic acid Leadiant : EPAR - Product Information HR = Hrvatski 2017-05-05 2017-08-22
Chenodeoxycholic acid Leadiant : EPAR - Product Information HR = Hrvatski 2017-05-05 2017-08-22
Chenodeoxycholic acid Leadiant : EPAR - Product Information HR = Hrvatski 2017-05-05 2017-08-22
Chenodeoxycholic acid Leadiant : EPAR - Product Information HR = Hrvatski 2017-05-05 2017-08-22
Chenodeoxycholic acid Leadiant : EPAR - Product Information HR = Hrvatski 2017-05-05 2017-08-22
Chenodeoxycholic acid Leadiant : EPAR - Product Information HR = Hrvatski 2017-05-05 2017-08-22
Chenodeoxycholic acid Leadiant : EPAR - Product Information HR = Hrvatski 2017-05-05 2017-08-22
Chenodeoxycholic acid Leadiant : EPAR - Product Information HR = Hrvatski 2017-05-05 2017-08-22
Chenodeoxycholic acid Leadiant : EPAR - Product Information HR = Hrvatski 2017-05-05 2017-08-22
Chenodeoxycholic acid Leadiant : EPAR - Product Information HR = Hrvatski 2017-05-05 2017-08-22

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.


Name Language First published Last updated
Chenodeoxycholic acid Leadiant : EPAR - All Authorised presentations HR = Hrvatski 2017-05-05 2017-06-29
Chenodeoxycholic acid Leadiant : EPAR - All Authorised presentations HR = Hrvatski 2017-05-05 2017-06-29
Chenodeoxycholic acid Leadiant : EPAR - All Authorised presentations HR = Hrvatski 2017-05-05 2017-06-29
Chenodeoxycholic acid Leadiant : EPAR - All Authorised presentations HR = Hrvatski 2017-05-05 2017-06-29
Chenodeoxycholic acid Leadiant : EPAR - All Authorised presentations HR = Hrvatski 2017-05-05 2017-06-29
Chenodeoxycholic acid Leadiant : EPAR - All Authorised presentations HR = Hrvatski 2017-05-05 2017-06-29
Chenodeoxycholic acid Leadiant : EPAR - All Authorised presentations HR = Hrvatski 2017-05-05 2017-06-29
Chenodeoxycholic acid Leadiant : EPAR - All Authorised presentations HR = Hrvatski 2017-05-05 2017-06-29
Chenodeoxycholic acid Leadiant : EPAR - All Authorised presentations HR = Hrvatski 2017-05-05 2017-06-29
Chenodeoxycholic acid Leadiant : EPAR - All Authorised presentations HR = Hrvatski 2017-05-05 2017-06-29
Chenodeoxycholic acid Leadiant : EPAR - All Authorised presentations HR = Hrvatski 2017-05-05 2017-06-29
Chenodeoxycholic acid Leadiant : EPAR - All Authorised presentations HR = Hrvatski 2017-05-05 2017-06-29
Chenodeoxycholic acid Leadiant : EPAR - All Authorised presentations HR = Hrvatski 2017-05-05 2017-06-29
Chenodeoxycholic acid Leadiant : EPAR - All Authorised presentations HR = Hrvatski 2017-05-05 2017-06-29
Chenodeoxycholic acid Leadiant : EPAR - All Authorised presentations HR = Hrvatski 2017-05-05 2017-06-29
Chenodeoxycholic acid Leadiant : EPAR - All Authorised presentations HR = Hrvatski 2017-05-05 2017-06-29
Chenodeoxycholic acid Leadiant : EPAR - All Authorised presentations HR = Hrvatski 2017-05-05 2017-06-29
Chenodeoxycholic acid Leadiant : EPAR - All Authorised presentations HR = Hrvatski 2017-05-05 2017-06-29
Chenodeoxycholic acid Leadiant : EPAR - All Authorised presentations HR = Hrvatski 2017-05-05 2017-06-29
Chenodeoxycholic acid Leadiant : EPAR - All Authorised presentations HR = Hrvatski 2017-05-05 2017-06-29
Chenodeoxycholic acid Leadiant : EPAR - All Authorised presentations HR = Hrvatski 2017-05-05 2017-06-29
Chenodeoxycholic acid Leadiant : EPAR - All Authorised presentations HR = Hrvatski 2017-05-05 2017-06-29
Chenodeoxycholic acid Leadiant : EPAR - All Authorised presentations HR = Hrvatski 2017-05-05 2017-06-29
Chenodeoxycholic acid Leadiant : EPAR - All Authorised presentations HR = Hrvatski 2017-05-05 2017-06-29
Chenodeoxycholic acid Leadiant : EPAR - All Authorised presentations HR = Hrvatski 2017-05-05 2017-06-29

Pharmacotherapeutic group

Bile and liver therapy

Therapeutic indication

Chenodeoxycholic acid is indicated for the treatment of inborn errors of primary bile acid synthesis due to sterol 27 hydroxylase deficiency (presenting as cerebrotendinous xanthomatosis (CTX)) in infants, children and adolescents aged 1 month to 18 years and adults.

Assessment History

Changes since initial authorisation of medicine

Name Language First published Last updated
Chenodeoxycholic acid Leadiant : EPAR - Procedural steps taken and scientific information after authorisation HR = Hrvatski 2017-06-29 2017-08-22

Initial marketing-authorisation documents

Name Language First published Last updated
Chenodeoxycholic acid sigma-tau : EPAR - Public assessment report HR = Hrvatski 2017-05-05  
CHMP summary of positive opinion for Chenodeoxycholic acid sigma-tau HR = Hrvatski 2016-09-16